Jan Endrikat

ORCID: 0000-0001-6063-5014 · 6 papers in corpus
2026
Recent Developments and Future Perspectives in Magnetic Resonance Imaging and Computed Tomography Contrast Media.
Investigative radiology ·doi:10.1097/rli.0000000000001180

AbstractThis review provides a comprehensive analysis of recent advancements in computed tomography (CT) and magnetic resonance imaging (MRI) contrast media, offering a critical evaluation of current trends and exploring future directions i…

letter 2017
Letter to the editor in response to “Minimal clinically important difference for pain on the VAS scale and the relation to quality of life in women with endometriosis” by Wickström and Edelstam
Sexual & reproductive healthcare : official journal of the Swedish Association of Midwives ·doi:10.1016/j.srhc.2017.10.004
review 2011
Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide
·doi:10.1016/j.contraception.2011.04.009

BackgroundThe objective of this analysis was to provide a comprehensive review of ovulation inhibition data of progestins currently available worldwide. This analysis may serve as a reference tool for research on new progestin molecules.Stu…

article 2008
Original research article Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies ☆,☆☆

Background: Attempts to improve the tolerability of combined oral contraceptives (COCs) have included the substitution of ethinylestradiol (EE) with 17β-estradiol (E2). However, this has proved unsatisfactory, specifically in terms of cycle…

article 2007
A multicenter, prospective, randomized, double-blind, placebo-controlled study to investigate the efficacy of a continuous-combined hormone therapy preparation containing 1 mg estradiol valerate/2 mg dienogest on hot flushes in postmenopausal women
Maturitas ·doi:10.1016/j.maturitas.2007.08.004

ObjectivesTo evaluate the effects of an estrogen-reduced, continuous-combined hormone therapy preparation (HT) containing 1mg estradiol valerate (1EV) and 2mg dienogest (2DNG) on the number of moderate and severe hot flushes.MethodsThis stu…

article 2007
A one-year randomized double-blind, multicentre study to evaluate the effects of an oestrogen-reduced, continuous combined hormone replacement therapy preparation containing 1 mg oestradiol valerate and 2 mg dienogest on metabolism in postmenopausal women
·doi:10.1080/13625180701441030

OBJECTIVES: To evaluate the impact of an oestrogen-reduced, continuous combined hormone replacement therapy preparation containing 1 mg oestradiol valerate (1EV) and 2 mg dienogest (2DNG) on metabolism. METHODS: In a randomized double-blind…